Neuphoria Therapeutics Inc. (NEUP) vs Psyence Biomedical Ltd. (PBM)

Neuphoria Therapeutics Inc. and Psyence Biomedical Ltd. are both Biotechnology companies. Neuphoria Therapeutics Inc. and Psyence Biomedical Ltd. are of similar size ($17.9M and $16.5M). Neuphoria Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Psyence Biomedical Ltd. trades at 0.2×. Across the 10 metrics below, Psyence Biomedical Ltd. leads on 7 and Neuphoria Therapeutics Inc. on 3.

Valuation

Metric NEUP PBM Biotechnology median
P/E n/m 0.19 8.50
P/S 0.91 n/m 9.71
P/B 0.58 0.08 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.27 1.82 0.64
EV/Sales (0.30) n/m 9.21
Earnings yield (154.60%) 534.77% (33.15%)
Free cash flow yield (85.14%) (807.70%) (25.50%)

Profitability

Metric NEUP PBM Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (61.70%) (23.52%) (56.36%)
Return on assets (46.95%) (6.74%) (48.04%)
Return on invested capital (232.67%) 0.00% 0.00%

Growth

Metric NEUP PBM Biotechnology median
Revenue growth (TTM) 3,535.05% — 6.02%
EPS growth (last fiscal year) (1,230.43%) (138.35%) 30.26%
Revenue growth, 5-year CAGR 19.07% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NEUP PBM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 27.85 8.09 4.72
Net debt to EBITDA 1.26 1.20 0.96

Dividend

Metric NEUP PBM Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NEUP PBM Biotechnology median
Market cap 17.91m 16.47m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack